Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are moving higher Tuesday after the company announced the FDA approved an accelerated pathway for ST-920, a potential gene therapy for the treatment of ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares are trading higher Tuesday after the company announced it has entered into a license agreement with Genentech to develop intravenously administered ...
9 analysts have shared their evaluations of Sangamo Therapeutics (NASDAQ:SGMO) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise ...
Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go. Pfizer ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew ...
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ...
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits ...
Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to ...
Sangamo Therapeutics disclosed in a filing with the Securities and Exchange Commission this week that its collaboration and license agreements with Novartis Institutes for BioMedical Research and ...
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business ...
Sangamo Therapeutics (NASDAQ: SGMO), a biotechnology company that focuses on multiple areas in the genomic medicine space, including gene therapy, cell therapy, and in vivo genome editing, looks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback